ストックスクリーナーアプリを入手
4.855
0.53%
0.025
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals Inc.’s Beta Climbs After Market VolatilityMarket Performance Report & Free Weekly Chart Analysis and Trade Guides - classian.co.kr
Why is RXRX Stock Declining? - StocksToTrade
Recursion Pharmaceuticals Inc. Shows Early Signs of Technical Strength2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - mustnews.co.kr
Recursion Pharma to reduce workforce by 20% - MSN
Recursion Pharmaceuticals Shares Dip Amid Rising R&D Costs - TipRanks
Top Executive Sells Thousands of Shares in Major Pharmaceutical Firm! - TipRanks
Recursion pharma director Khan sells $202k in shares By Investing.com - Investing.com UK
Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data (NASDAQ:RXRX) - Seeking Alpha
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? - MSN
Healthcare Stocks Receive Analyst Ratings: Cullinan Management, Recursion Pharmaceuticals, and Cochlear. - AInvest
RXRX Stock: Is It a Hidden Gem? - timothysykes.com
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - MSN
Why Recursion Pharmaceuticals Stock Faces Pressure - TipRanks
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - MSN
Recursion Pharmaceuticals: Pioneering AI-Driven Drug Discovery to Redefine Precision Medicine and Deliver Outsized Returns - AInvest
Recursion Pharmaceuticals Expands AI Drug Discovery Pipeline with New Clinical Candidates - AInvest
Will Recursion Pharmaceuticals' (RXRX) Widening Losses Challenge Its Long-Term Innovation Story? - simplywall.st
Is Recursion Pharmaceuticals' AI-Driven Drug Discovery Model Worth the High-Risk Bet? - AInvest
Largest borrow rate increases among liquid names - MSN
Indicative Borrow Rate Increases Among Liquid Names: RXRX, POET, USAR, and More - AInvest
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Support Zone Holds Steady for Recursion Pharmaceuticals Inc. After DipJuly 2025 Macro Moves & Trade Opportunity Analysis Reports - 선데이타임즈
Recursion Pharmaceuticals Insider Sold Shares Worth $3,263,964, According to a Recent SEC Filing - MarketScreener
Recursion Pharma CEO Gibson sells shares worth $3.26 million By Investing.com - Investing.com South Africa
Recursion Pharma CEO Gibson sells shares worth $3.26 million - Investing.com
Is Recursion On A Breakthrough Path? - timothysykes.com
Recursion Pharmaceuticals: Two Clinical Readouts In H2'25 (NASDAQ:RXRX) - Seeking Alpha
How Rising Losses and Revenue Growth at Recursion Pharmaceuticals (RXRX) Have Changed Its Investment Story - simplywall.st
From Novel Discovery to Precision Biomarkers: How Recursion is Using Data and AI to Deliver New Cancer Drugs - MarketScreener
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX) - The Globe and Mail
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
0.62%
0.93%
大文字化:
|
ボリューム (24 時間):